• Explore /
  • Poster
  • / Screening of 129 FDA approved anti-cancer drugs in colorectal cancer cell lines resistant to oxaliplatin or irinotecan (SN38).

Screening of 129 FDA approved anti-cancer drugs in colorectal cancer cell lines resistant to oxaliplatin or irinotecan (SN38).

Abstract Poster

Authors

null

Jan Stenvang

Section for Molecular Disease Biology, Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Jan Stenvang , Christine Hjorth Andreassen , Nils Brünner

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Translational Research

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract 642)

DOI

10.1200/JCO.2017.35.4_suppl.642

Abstract #

642

Poster Bd #

F16

Abstract Disclosures

Similar Posters

Poster

2016 Gastrointestinal Cancers Symposium

Novel drug discovery by pharmacogenomic profiling of 36 colorectal cancer cell lines.

Novel drug discovery by pharmacogenomic profiling of 36 colorectal cancer cell lines.

First Author: Peter Eide

First Author: Margaret Lee

First Author: Helena Anna Taflin

First Author: Mitsukuni Suenaga